Related Experiment Video
Updated: Jan 17, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
Published on: February 15, 2022
Visual Outcomes Following Hyperbaric Oxygen Therapy in Acute Central Retinal Artery Occlusion Patients
Somanus Thoongsuwan1, Thanut Sirichayaporn1, Nuttawut Rodanant1
1Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Insights
A novel hyperbaric oxygen therapy (HBOT) protocol improved visual acuity in patients with central retinal artery occlusion (CRAO) within 24 hours. This HBOT approach showed significant benefits compared to standard care.
Area of Science:
- Ophthalmology
- Neovascularization
- Vascular Medicine
Background:
- Central Retinal Artery Occlusion (CRAO) is a critical condition leading to sudden vision loss.
- Prompt intervention is crucial for visual recovery in CRAO patients.
- Novel therapeutic strategies are needed to improve outcomes for CRAO.
Purpose of the Study:
- To evaluate the efficacy of a novel hyperbaric oxygen therapy (HBOT) protocol in patients with CRAO.
- To compare the visual outcomes of the novel HBOT protocol against standard non-HBOT care.
- To assess the impact of HBOT on visual acuity (VA) within 24 hours of CRAO onset.
Main Methods:
- A retrospective cohort study design was employed.
- Patients with CRAO presenting within 24 hours were included.
- 17 patients received the novel HBOT protocol; 32 received standard care. Exclusions included rt-PA treatment or complications.
Main Results:
- The HBOT group showed a significantly higher rate of VA improvement (≥0.3 logMAR) at discharge (76.5% vs. 40.6%, p=0.02).
- Mean logMAR VA at discharge was significantly better in the HBOT group (1.4 ± 0.8) compared to the non-HBOT group (2.0 ± 0.8).
- Improved VA was maintained at one-month follow-up in the HBOT group.
Conclusions:
- The novel HBOT protocol demonstrated potential benefits for visual recovery in CRAO patients presenting within 24 hours.
- The findings suggest HBOT may be a valuable adjunct treatment for acute CRAO.
- Further prospective studies are warranted to validate these findings and guide clinical adoption.
Purpose:
To evaluate the efficacy of a novel HBOT protocol, characterized by specific pressure levels and treatment duration in patients with CRAO patients presenting within 24 hours, compared to a non-HBOT cohort.
Patients And Methods:
This retrospective cohort study included patients diagnosed with CRAO presenting within 24 hours from October 2003 to March 2022. Patients treated with intravenous recombinant tissue plasminogen activator (rt-PA) or experiencing treatment-related visual complications were excluded. Of 49 eligible patients, 17 underwent HBOT following the novel protocol, while 32 received standard care (non-HBOT).
Results:
Baseline logMAR VA was 2.3 in both groups. At discharge, 76.5% of the HBOT group exhibited a VA improvement of at least 0.3 logMAR, compared to 40.6% in the non-HBOT group (p = 0.02). Mean logMAR VA at discharge was 1.4 ± 0.8 in the HBOT group and 2.0 ± 0.8 in the non-HBOT group. After one month, the mean logMAR VA remained at 1.4 ± 0.9 in the HBOT group and was 1.9 ± 0.9 in the non-HBOT group.
Conclusion:
While constrained by the small sample size and short-term outcome data, these results showed the benefits of this unique HBOT protocol in CRAO presenting within the critical 24-hour window. Nevertheless, further prospective validation is necessary before widespread clinical adoption.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview

